<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049088</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02508</org_study_id>
    <secondary_id>J0203</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>CDR0000257807</secondary_id>
    <nct_id>NCT00049088</nct_id>
  </id_info>
  <brief_title>Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of PS-341 in Combination With Docetaxel in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of combining bortezomib with docetaxel in treating&#xD;
      patients who have advanced solid tumors. Bortezomib may stop the growth of tumor cells by&#xD;
      blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Combining&#xD;
      bortezomib with docetaxel may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of bortezomib and docetaxel in patients with advanced&#xD;
      solid tumors.&#xD;
&#xD;
      II. Determine the toxicity and tolerability of this regimen in these patients. III. Determine&#xD;
      the biologic correlates of proteasome inhibition of bortezomib and determine the effects of&#xD;
      this inhibition on the pharmacokinetics of docetaxel in these patients.&#xD;
&#xD;
      IV. Determine the antitumor efficacy of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      For course 1, patients receive docetaxel IV over 1 hour on days 1 and 8 and bortezomib IV&#xD;
      over 3-5 seconds on days 9 and 12. Patients then receive 1 week of rest. For course 2 and all&#xD;
      subsequent courses, patients receive docetaxel on days 1 and 8 and bortezomib on days 2, 5,&#xD;
      9, and 12. Courses repeat every 3 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity. Cohorts of 2-6 patients receive escalating doses of bortezomib and docetaxel until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no&#xD;
      more than 1 of 6 patients experiences dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>August 2002</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT) as assessed by the NCI Common Toxicity Criteria (CTC) version 2.0</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity and tolerability as assessed by NCI CTC version 2.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of docetaxel</measure>
    <time_frame>At baseline, at 30 and 60 during infusion, at 10 min, 30 min, 1, 3, 7.5, 24, and 48 hours, and at 8 days after completion of docetaxel infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>20S proteasome activity</measure>
    <time_frame>At 1 hour after first PS-341 infusion (week 2, day 2), and at 24 and 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (docetaxel, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For course 1, patients receive docetaxel IV over 1 hour on days 1 and 8 and bortezomib IV over 3-5 seconds on days 9 and 12. Patients then receive 1 week of rest. For course 2 and all subsequent courses, patients receive docetaxel on days 1 and 8 and bortezomib on days 2, 5, 9, and 12. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 2-6 patients receive escalating doses of bortezomib and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (docetaxel, bevacizumab)</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (docetaxel, bevacizumab)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (docetaxel, bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (docetaxel, bevacizumab)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor for which standard curative or palliative&#xD;
             measures do not exist or are no longer effective&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100%&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT no greater than 1.5 times upper limit of normal (ULN) and alkaline&#xD;
             phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 5 times ULN (unless bone-derived) and AST and ALT&#xD;
             less than 1.5 times ULN&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
          -  No prior allergic reactions attributed to taxanes (e.g., docetaxel or paclitaxel) or&#xD;
             compounds of similar chemical or biological composition&#xD;
&#xD;
          -  No prior allergic reactions to compounds similar to bortezomib or other study agents&#xD;
&#xD;
          -  No known hypersensitivity to corticosteroids&#xD;
&#xD;
          -  No predicted intolerance to regular, repeated administration of corticosteroids (e.g.,&#xD;
             poorly controlled diabetes or significant osteoporosis/osteopenia)&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other uncontrolled concurrent illness that would preclude study participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
          -  No peripheral neuropathy grade 2 or greater&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for carmustine, nitrosoureas, or&#xD;
             mitomycin) and recovered&#xD;
&#xD;
               -  No more than 3 courses of mitomycin&#xD;
&#xD;
          -  Prior taxanes allowed&#xD;
&#xD;
               -  At least 6 months since prior docetaxel administered on a weekly schedule&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies (commercial or investigational)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Armstrong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

